Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid Monomethyl Ester. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.33 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.33 |
| ▸ | INPP5B | P32019 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.32 |
| ▸ | ITPR3 | Q14573 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid Monomethyl Ester SCHEMBL19942 | 0.96 | — | — | |
| Phosphoric Acid Monomethyl Ester SCHEMBL27955495 | 0.96 | FDPS (0.50) | FDPSBLMTDP1CA2CA4 | |
| Phosphoric Acid Monomethyl Ester SCHEMBL9580810 | 0.92 | FDPS (0.47) | FDPSBLMTDP1CA2CA4 | |
| Phosphoric Acid Monomethyl Ester SCHEMBL9425283 | 0.92 | — | — | |
| Phosphoric Acid Monomethyl Ester SCHEMBL1499040 | 0.92 | — | — | |
| Phosphoric Acid Monomethyl Ester SCHEMBL25407716 | 0.92 | — | — | |
| Phosphoric Acid Monomethyl Ester SCHEMBL8304876 | 0.92 | — | — | |
| Phosphoric Acid Monomethyl Ester SCHEMBL1656817 | 0.92 | — | — | |
| Phosphoric Acid Monomethyl Ester SCHEMBL11053564 | 0.92 | — | — | |
| Phosphoric Acid Monomethyl Ester SCHEMBL9425276 | 0.92 | FDPS (0.47) | FDPSBLMTDP1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101429119-B | Process for producing polyglycerol fatty acid monoester | UNIV JIANGNAN | 2011-06-22 | — | — | CN | claimed |
| CN-101429119-A | Process for producing polyglycerol fatty acid monoester | UNIV JIANGNAN (CN) | 2009-05-13 | — | — | CN | claimed |
| CN-118019848-A | RNA editing | 豪夫迈·罗氏有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-113692430-B | Primer composition | 思美定株式会社 | 2023-06-09 | — | — | CN | disclosed |
| CN-112188836-B | Agrochemical formulations containing polymeric crystal growth inhibitors | 拜耳公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20220273673-A1 | BONE-BINDING COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 2022-09-01 | — | — | US | disclosed |
| CN-114585316-A | Osseointegrating compounds | 布莱阿姆青年大学 | 2022-06-03 | — | — | CN | disclosed |
| EP-4003201-A1 | BONE-BINDING COMPOUNDS | Brigham Young University (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021016583-A1 | BONE-BINDING COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 2021-01-28 | — | — | WO | disclosed |
| US-20110256065-A1 | Non-Isotopic Detection of Osteoblastic Activity In Vivo Using Modified Bisphosphonates | FRANGIONI JOHN V | 2011-10-20 | — | — | US | disclosed |
| CN-101429119-B | Process for producing polyglycerol fatty acid monoester | UNIV JIANGNAN | 2011-06-22 | — | — | CN | disclosed |
| US-20070036724-A1 | diagnostic detection of diseases accompanied with an abnormality of calcium hydroxyapatite using in vivo imaging; contrast agent comprising a fluorescent moiety covalently linked to a bisphosphonate moiety such as, alendronate, clodronate, EB-1053, etidronate, ibandronate, incadronate, neridronate | FRANGIONI JOHN V | 2007-02-15 | — | — | US | disclosed |
| US-20060002857-A1 | Non-isotopic detection of osteoplastic activity in vivo using modified bisphosphonates | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2006-01-05 | — | — | US | disclosed |
| US-6869593-B2 | Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040028611-A1 | Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates | BETH ISRAEL DEACONESS MEDICAL CENTER, OF THE ENTIRE INERST. | 2004-02-12 | — | — | US | disclosed |
| EP-1341557-A2 | NON-ISOTOPIC DETECTION OF OSTEOBLASTIC ACTIVITY IN VIVO USING MODIFIED BISPHOSPHONATES | Beth Israel Deaconess Medical Center (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-1131100-B1 | THERAPEUTIC COMPOSITIONS FOR METABOLIC BONE DISORDERS OR BONE METASTASES COMPRISING A PHOTOSENSITIZER AND A BISPHOSPHONATE | LIGHT SCIENCES CORP (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20030018371-A1 | Compositions and methods for the treatment of metabolic bone disorders and bone metastases | LIGHT SCIENCES CORPORATION | 2003-01-23 | — | — | US | disclosed |
| WO-2002038190-A2 | NON-ISOTOPIC DETECTION OF OSTEOBLASTIC ACTIVITY IN VIVO USING MODIFIED BISPHOSPHONATES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2002-05-16 | — | — | WO | disclosed |
| CN-1155856-A | Binder composition for mold production and process for producing mold | KAO CORP (JP) | 1997-07-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040028611-A1 | Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates | SOST, ACP3, PHPT1 | FDPS 1570/4885BLM 4653/4885TDP1 3911/4885 |
| US-20110256065-A1 | Non-Isotopic Detection of Osteoblastic Activity In Vivo Using Modified Bisphosphonates | SOST, ACP3, PHPT1 | FDPS 1570/4885BLM 4653/4885TDP1 3911/4885 |
| US-20070036724-A1 | diagnostic detection of diseases accompanied with an abnormality of calcium hydroxyapatite using in vivo imaging; contrast agent comprising a fluorescent moiety covalently linked to a bisphosphonate moiety such as, alendronate, clodronate, EB-1053, etidronate, ibandronate, incadronate, neridronate | HCAR3, ENTPD3, SLC9A3 | FDPS 1560/4885BLM 3017/4885TDP1 3137/4885 |
| US-20060002857-A1 | Non-isotopic detection of osteoplastic activity in vivo using modified bisphosphonates | SOST, ACP3, ALPP | FDPS 1517/4885BLM 4790/4885TDP1 3617/4885 |
| US-20220273673-A1 | BONE-BINDING COMPOUNDS | CCL5, BMP2, CLTB | FDPS 1548/4885BLM 3806/4885TDP1 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.